Hikal Limited has informed the Exchange about Investor Presentation
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hikal Limited submitted a revised Q1FY26 investor presentation to the exchanges. Consolidated revenue declined 6.5% year-on-year to Rs. 380 Cr, while EBITDA fell sharply by 57.4% to Rs. 25 Cr (margin compressed to 6.5% from 14.3%), and the company slipped into a net loss of Rs. 23 Cr versus a Rs. 5 Cr profit a year ago. The Pharmaceuticals division (53% of revenue) bore the brunt, posting a negative 12.9% EBIT margin after the US FDA issued an 'Official Action Indicated' (OAI) classification in May 2025, which triggered customer offtake deferrals. Crop Protection (47% of revenue) was largely flat at Rs. 178 Cr with a 9.7% EBIT margin, weighed down by pricing pressure from Chinese competition. Management reaffirmed full-year FY26 guidance, citing a robust CDMO pipeline in both segments, successful ANVISA and PMDA audits at Bangalore, and expecting a more meaningful recovery in H2 FY26 supported by resumed pharma offtake and cost discipline.
Weak Q1 numbers and the lingering FDA overhang are near-term negatives for the stock, but reaffirmed FY26 guidance and visible focus on debt reduction and cash flow improvement may cap further downside. Shareholders should watch for pharma off-take resumption and progress on FDA remediation in the coming quarters.